Business Wire

Estée Lauder Launches Emerging Leaders Fund to Advance the Next Generation of Women Redefining Leadership

Share

Estée Lauder, the flagship brand of The Estée Lauder Companies Inc., is proud to announce the launch of the Estée Lauder Emerging Leaders (ELEL) Fund, a charitable fund under The Estée Lauder Companies Charitable Foundation. The ELEL Fund’s mission is to redefine leadership by supporting a new generation of emerging women leaders and challenging the gender stereotypes of leadership. The Fund will support global organizations that provide opportunities for leadership development, cultivate supportive communities and advocate for emerging leaders who have a daring vision for change.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220504005425/en/

Estée Lauder has made an initial $1MM investment into the ELEL Fund which will support mission-aligned organizations. Vital Voices, a global nonprofit that invests in women leaders, has been selected as the inaugural program partner of the ELEL Fund, with the program commencing in July 2022. Additional grants by the ELEL Fund will be announced in the coming year.

Global Leadership and Gender Report by Estée Lauder
To gain a deeper understanding of perceptions of leadership and gender bias around the world, the Estée Lauder brand commissioned Glocalities, an international market research agency, for a global study of more than 5,700 men and women across 11 countries. The research revealed that whilst there are still prevalent gender biases and stereotypes when it comes to leadership, both men and women value the same qualities in a leader - reliability, integrity and dedication - which are not attached to gender. However, while leadership qualities such as strength and determination are equally valued by both men and women they are more strongly associated with men. The study reveals the roadblocks and solutions for advancing gender-inclusive leadership.

Estée Lauder’s Legacy
As one of the leading prestige beauty brands in the world, Estée Lauder continues to be inspired by its founder, Mrs. Estée Lauder, and her belief in a woman’s infinite possibilities. The ELEL Fund will reinforce the brand’s commitment to women’s advancement by addressing some of the gender-based biases uncovered in the research and shifting the perception of leadership.

“The 75-year legacy of the Estée Lauder brand shows what one visionary woman can achieve,” said Stéphane de La Faverie, Group President, The Estée Lauder Companies and Global Brand President, Estée Lauder & AERIN Beauty. “Through the work of the Estée Lauder Emerging Leaders Fund and its program partners, we will champion women to contribute and lead in their workplaces and communities. We want to redefine what it means to be a leader and what it takes to lead. We want to see more women like Mrs. Estée Lauder in the world.”

The VV Visionaries Leadership Program in partnership with the ELEL Fund
The Estée Lauder Emerging Leaders Fund selected Vital Voices, a global nonprofit that invests in women leaders who are taking on the world’s greatest challenges, as its first official program partner and grant recipient. With the shared mission of advancing women and redefining leadership, the ELEL Fund and Vital Voices have built a custom online and offline leadership development program for emerging leaders globally. Program participants will join the Vital Voices community of over 20,000 women across 184 countries, which includes Estée Lauder Global Changemaker, Amanda Gorman. Applications are now open for the first and second cohort and can be accessed at www.vitalvoices.org/program/visionaries.

“At Vital Voices we have seen that women lead differently, and that difference is precisely what our world needs,” said Alyse Nelson, Vital Voices President and CEO. “Our partnership with the Estée Lauder Emerging Leaders Fund will identify emerging leaders with a bold vision for positive change and provide them with the skills, network and resources they need to make that vision a reality.”

To learn more about the ELEL Fund, visit esteelauder.com.

Follow @esteelauder and #LeadYourWay hashtag to join the conversation.

About Estée Lauder
Estée Lauder is the flagship brand of The Estée Lauder Companies Inc. Founded by Estée Lauder, one of the world’s first female entrepreneurs, the brand today continues her legacy of creating innovative, sophisticated, high-performance skincare and makeup products and iconic fragrances – all infused with a deep understanding of women’s needs and desires. Today, Estée Lauder engages with customers in more than 150 countries and territories around the world and across dozens of touch points – from in-store to digital. And each of these relationships consistently reflects Estée’s powerful and authentic woman-to-woman point of view. Follow @esteelauder on Instagram, Facebook, Twitter, TikTok and YouTube.

About The Estée Lauder Emerging Leaders Fund
The Estée Lauder Emerging Leaders Fund is a charitable fund of The Estée Lauder Companies Charitable Foundation, a U.S. based charity incorporated and tax exempt in the United States of America.

About Vital Voices
Driven by the universal truth that women are the key to progress in their communities and that nations can’t move forward without women in leadership positions, Vital Voices Global Partnership has directly invested in more than 20,000 changemakers across 184 countries and territories over the last 24 years. It has provided early support for leaders who went on to become Nobel Peace Prize Laureates, U.S. Youth Poet Laureates, Prime Ministers, award-winning innovators, pioneering human rights defenders, and breakthrough social entrepreneurs, including Amanda Gorman, Malala Yousafzai, and more. Serving as a “venture catalyst,” the non-profit identifies leaders with a daring vision for change and partners with them to make that vision a reality. It provides connections, increased capacity, a peer network, financial support, skills training, and increased visibility for their work, which ranges from gender-based violence to the climate crisis, economic inequities. Follow @vitalvoices on Instagram, Facebook, Twitter, LinkedIn, and YouTube.

ELB-B

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PR Contacts

Tara Connaughton, Estée Lauder, tconnaug@estee.com
Stephanie Katz, Estée Lauder, skatz@estee.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Coulson Aviation Announces Launch of Boeing 767 VLAT Program22.12.2025 15:03:00 EET | Press release

Coulson Aviation USA has announced the launch of its Boeing 767 Very Large Airtanker (VLAT) program, marking a significant advancement in the evolution of aerial firefighting capability. The program is intended to provide a sustainable replacement for legacy VLAT platforms nearing the end of their operational service life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251222917730/en/ A cross-sectional view of Coulson Aviation’s Boeing 767 Very Large Airtanker (VLAT) illustrates the integration of the RADS retardant delivery system and the next generation of high-capacity, sustainable aerial firefighting design. The recent grounding of the MD11 and DC10 fleets has highlighted a structural challenge for firefighting agencies worldwide. As older widebody aircraft are retired, the industry faces a significant reduction in high-capacity, large-scale retardant delivery capability. Coulson’s 767 VLAT is being developed to address

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye